Quantcast
Channel: BioTuesdays » ropinirole
Browsing all 6 articles
Browse latest View live

Image may be NSFW.
Clik here to view.

Titan implanting treatments for opioid dependence

In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a...

View Article



Image may be NSFW.
Clik here to view.

Titan Pharma Phase 3 data validate ProNeura technology

Titan Pharmaceuticals’ (OTCQB:TTNP) positive topline results from a Phase 3 clinical study of Probuphine, its subdermal implant of buprenorphine for the long-term maintenance treatment of opioid...

View Article

Image may be NSFW.
Clik here to view.

Titan presents nonclinical ProNeura data in Parkinson’s

Titan Pharmaceuticals (OTCQB:TTNP) has presented nonclinical data at the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, demonstrating the potential of Titan’s...

View Article

Image may be NSFW.
Clik here to view.

Titan Pharma advancing pipeline in PD, other disorders

Titan Pharmaceuticals (NASDAQ:TTNP), which is awaiting an FDA approval decision for its six-month Probuphine implant to treat opioid dependence, is advancing its ProNeura implant technology against...

View Article

Image may be NSFW.
Clik here to view.

Titan adds ProNeura implant for hypothyroidism to pipeline

Titan Pharmaceuticals (NASDAQ:TTNP) has added an implantable triiodothyronine (T3) product for the treatment of hypothyroidism to its product development pipeline. Hypothyroidism affects about 15...

View Article


Image may be NSFW.
Clik here to view.

Roth ups Titan Pharma price target to $7.25

Roth Capital Partners has raised its price target on “buy-rated” Titan Pharmaceuticals (NASDAQ:TTNP) to $7.25 from $6.50 to reflect an increased value attributed to Titan’s pipeline. The stock closed...

View Article
Browsing all 6 articles
Browse latest View live




Latest Images